FIGURE

Fig. 5

ID

ZDB-FIG-241209-62

Publication

Quinlan et al., 2024 - Identification of NanoLuciferase Substrates Transported by Human ABCB1 and ABCG2 and their Zebrafish Homologs at the Blood-Brain Barrier

Other Figures

All Figure Page

Back to All Figure Page

Fig. 5

Percent increase in residual luminescence. Measurements taken after 5 minutes of efflux for cells treated or not treated with ABC transporter inhibitors (for ABCG2 and Abcg2a, Ko143, 5 μM; for ABCB1 and Abcb4, elacridar, 3 μM; 470 nM NanoLuc substrate of interest) for (A) furimazine, (B) cephalofurimazine, (C) 8122, (D) 8129, (E) fluorofurimazine, (F) coelenterazine-f, (G) coelenterazine-h, (H) 6403, (I) coelenterazine-fcp, (J) coelenterazine-hcp, (K) coelenterazine-n, (L) coelenterazine, (M) coelenterazine-i, (N) coelenterazine-cp, (O) 6400, and (P) coelenterazine-ip. Larger values indicate a more strongly effluxed substrate. Data presented as mean ± S.D. of luminescence at 5 minutes in the inhibited condition divided by luminescence at 5 minutes in the uninhibited condition. Data three biological replicates of all substrates. The black dashed line at 1 indicates the level at which luminescence from inhibited and uninhibited samples were equal. The line at 1.5 indicates the threshold set to indicate a detectable difference in future experiments.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Mol. Pharmacol.